The psoriasis treatment framework in India is experiencing a notable change, moving away from traditional topical medications and older systemic therapies to more focused biologic solutions, particularly in cases of moderate-to-severe diseases. In the past, first-line treatments predominantly consisted of topical corticosteroids, vitamin D analogues, and phototherapy due to their cost-effectiveness and easy access. However, a rise in awareness about the disease among both healthcare professionals and patients, along with advancing clinical protocols, has facilitated the quicker uptake of systemic biologics that target interleukin pathways and TNF-alpha. The introduction of new biologics like tildrakizumab by local firms underscores the nation's increasing embrace of new therapies and enhances physicians' trust in strategies for long-term disease management. The growth of urban dermatology facilities has significantly contributed to this evolution. Major urban centers such as Mumbai, Delhi, Bengaluru, and Hyderabad have witnessed a swift increase in specialized dermatology practices, skin treatment centers within hospitals, and integrated rheumatology services for addressing psoriatic arthritis.

These establishments are now more equipped to provide biologic injections, track immunological conditions, and conduct clinical studies, which improves patient outcomes and adherence to treatment. Furthermore, the rising incomes of the middle class and the expansion of private health insurance in urban areas have made advanced treatments more affordable compared to rural areas. The boost in clinical trials and local research partnerships promotes the faster acceptance of targeted therapies, shifting focus from mere symptom relief with topical treatments to strategies that modify the disease. Although there has been progress, the choice of treatment still greatly differs between urban and semi-urban communities due to factors such as physician experience, facility readiness, and pricing. Many healthcare providers continue to follow a gradual approach to treatment, beginning with topical and systemic options before utilizing biologics. According to the research report, " India Psoriasis Treatment Market Overview, 2031," published by Bonafide Research, the India Psoriasis Treatment market is anticipated to grow at more than 12.34% CAGR from 2026 to 2031. This growth is driven by a rise in the incidence of the disease, increased healthcare investment, and better accessibility to specialized dermatological care. Domestic pharmaceutical companies significantly influence market trends, with firms like Sun Pharma actively introducing new biologics and dermatological medicines to enhance local treatment alternatives.

The launch of advanced products such as ILUMYA showcases the growing innovative capabilities within the country and reflects the broader evolution of India’s pharmaceutical sector, which is shifting focus from generic products to specialty and biologic drugs. Nonetheless, the main obstacle to the broad use of biologics is still affordability. The high costs that patients have to pay out of pocket for healthcare and the limited insurance coverage for high-priced treatments hinder many individuals' accesses, especially those in rural areas and lower-income communities. Even when innovative treatments are suitable from a clinical perspective, doctors frequently opt for traditional systemic medications because of cost concerns. Consequently, biosimilars are coming forth as an essential solution, with biotechnology firms in India creating affordable alternatives aimed at lowering treatment costs and increasing patient access. Research and clinical assessments of biosimilar versions of established biologics indicate a potential transition toward more affordable targeted therapy choices.

Moreover, there are growing prospects in telemedicine and digital dermatology services, particularly after the rise in virtual healthcare utilization post-COVID-19. Teledermatology helps to mitigate the lack of specialists in rural areas by facilitating remote consultations, allowing for quicker diagnoses, and enabling ongoing treatment supervision. India's robust generics production capabilities enable the nation to take a leading role in the supply of reasonably priced psoriasis medication. India psoriasis treatment market by type is divided into plaque psoriasis, psoriatic arthritis and others. The psoriasis market in India is primarily led by plaque psoriasis, which accounts for the largest share of diagnosed cases owing to its persistent nature and noticeable signs, such as red, scaly patches typically seen on the scalp, elbows, knees, and lower back. Rising public awareness, advancements in dermatological screening, and a growing number of specialized skin clinics located in major cities like Delhi, Mumbai, Bengaluru, and Chennai are encouraging earlier diagnosis and timely treatments. Residents in urban areas tend to seek medical help more frequently, while those in rural regions continue to experience underdiagnosis due to limited access to dermatological care.

Factors like pollution, stress, and changes in lifestyle are also leading to a higher incidence of plaque psoriasis across the nation. The segment of psoriatic arthritis is gaining recognition in India, aided by better teamwork between dermatologists and rheumatologists. Previously overlooked, this condition is now gaining more clinical focus as awareness grows about the joint damage linked to untreated psoriasis. Advances in diagnostics, such as imaging techniques and biomarker testing, are assisting doctors in identifying patients sooner. Pharmaceutical firms are advocating for targeted treatments for psoriatic arthritis, including biologics and disease-modifying antirheumatic drugs DMARDs. Increasing healthcare expenditure and awareness campaigns from patient advocacy groups are also motivating individuals with joint discomfort to seek expert treatment, supporting the growth of this sector.

The others category, which comprises pustular, erythrodermic, and inverse psoriasis, remains relatively minor but is clinically important due to its severity and the complexities involved in management. Management of these less common forms often necessitates hospitalization, systemic medications, or advanced biologics, rendering treatment costly. Growing research partnerships and clinical trials in India are enhancing understanding and treatment strategies for these conditions. India psoriasis treatment market by treatment type is divided into biologics drugs, systemic drugs, topical drugs, phototherapy and others. In India, treatment categorization signifies a gradual shift from traditional therapies to more sophisticated and targeted interventions. Topical medications, such as corticosteroids, vitamin D derivatives, coal tar products, and combination creams, continue to be the primary treatment for mild to moderate psoriasis due to their cost-effectiveness and accessibility. These treatments are readily found in pharmacies and often suggested within primary healthcare.

Despite their extensive availability, issues with adherence and limited long-term efficacy in moderate-to-severe cases are pushing both doctors and patients to consider systemic and biologic alternatives. Enhanced patient education initiatives are also fostering better treatment adherence and improved outcomes. Systemic medications, like methotrexate, cyclosporine, and acitretin, continue to be essential for treating moderate to severe psoriasis, particularly in populations sensitive to costs. These treatments are generally less expensive than biologics and are frequently prescribed in both government hospitals and private dermatology offices. Nonetheless, worries about long-term side effects and the need for ongoing monitoring are leading healthcare providers to explore safer targeted options whenever possible. At the same time, biologic medications are becoming more popular in urban areas and among individuals suffering from severe psoriasis or psoriatic arthritis.

The rising presence of biosimilars from Indian drug manufacturers is slowly lowering treatment expenses and enhancing accessibility, although costs still pose a significant challenge for many patients. Phototherapy is still a dependable and economical choice in tertiary healthcare facilities and dermatology clinics, particularly narrowband UVB therapy. This method is widely used for treating moderate psoriasis and for those who cannot take systemic drugs. The others category includes new treatments like small-molecule inhibitors and combination therapy that cater to individual patient needs. India psoriasis treatment market by distribution channel is divided into hospital pharmacies, retail pharmacies and e-commerce. The distribution channels in India are quickly changing due to advancements in healthcare and digital transformation. Hospital pharmacies lead the market for high-cost treatments like biologics and advanced systemic medications because these therapies typically need specialist prescriptions, patient follow-ups, and specific storage conditions.

Government hospitals and large private health systems are crucial in ensuring affordable access through public health initiatives and insurance programs. Hospital-based dispensing also guarantees proper patient guidance and adherence tracking, especially for complex treatments. Retail pharmacies are still the main avenue for topical products, oral systemic drugs, and continuous therapies. India's vast network of local chemists provides broad access to widely prescribed medications, even in semi-urban and rural areas. Pharmacists frequently act as the first point of contact for healthcare advice regarding minor issues, which encourages early treatment but may also result in challenges with self-medication. Stricter regulations and improved training programs for pharmacists are enhancing dispensing practices and advocating for responsible medication usage.

The e-commerce and online pharmacy market is rapidly expanding, driven by the rise of smartphones, the adoption of digital health solutions, and the ease of home delivery options. Online platforms offer features like price comparisons, subscription refills, and integration with teleconsultations, making it easier for patients with limited mobility or time constraints to manage chronic illnesses. Throughout and following the COVID-19 pandemic, a significant number of patients turned to online drug purchases, boosting the growth of this distribution channel. Nonetheless, ensuring regulatory compliance and verifying prescriptions remain essential hurdles. With enhancements in digital health infrastructure and growing consumer confidence, e-commerce is anticipated to become a key growth factor in the distribution of psoriasis treatments in India.Considered in this report* Historic Year: 2020* Base year: 2025* Estimated year: 2026* Forecast year: 2031Aspects covered in this report* Psoriasis Treatment Market with its value and forecast along with its segments* Various drivers and challenges* On-going trends and developments* Top profiled companies* Strategic recommendationBy TypePlaque PsoriasisPsoriatic ArthritisOthersBy Treatment TypeBiologics DrugsSystemic DrugsTopical DrugsPhototherapyOthersBy Distribution ChannelHospital PharmaciesRetail Pharmaciese-Commerce.